iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
Globe Newswire•10/11/2026•16:30 ET
0
Key Highlights
- ➤Revenue $1.1 million, up $1.0 million year over year
- ➤Net loss $7.6 million versus $5.7 million year over year
- ➤IBIO-600 completes single ascending dose Phase 1 dosing
- ➤IBIO-610 combination produced 93% fat-based weight loss versus 77% with semaglutide alone
- ➤Cash, equivalents and debt investments totaled $76.7 million at September 30
Expert Statements
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“This was a quarter of focus and execution as we advanced our portfolio of long-acting antibody therapeutics designed to address important challenges in obesity care”
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“The data presented at EASD strengthen our conviction in IBIO-610’s potential to deliver high-quality weight loss and provide important preclinical validation as we advance toward an IND-equivalent filing by the end of 2026, with plans to initiate first-in-human studies in the first half of 2027.”
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“We also anticipate advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027 and progressing our preclinical programs that aim to address the entire spectrum of cardiometabolic disease care.”
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“Together, this progress brings us closer to our broader goal of helping people living with obesity achieve high-quality weight loss and better long-term health.”
Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy
Completed dosing in the single ascending dose portion of the Phase 1 clinical trial of IBIO-600
Get started
Create a free account to read the full story.